Challenges in pharmacogenetics

被引：8

作者：

Cascorbi, Ingolf ^{[1
]}

Bruhn, Oliver ^{[1
]}

Werk, Anneke N. ^{[1
]}

机构：

[1] Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, D-24105 Kiel, Germany

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 69卷

关键词：

CYP2C19; GENOTYPE; CYP2D6; POLYMORPHISM; ASSOCIATION; CLOPIDOGREL; METABOLISM; IMPACT; RISK; PHARMACOKINETICS; HYDROXYLATION;

D O I：

10.1007/s00228-013-1492-x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The attempt to optimize drug treatment of patients by using evidenced-based medicine considering individual physiological and disease-related conditions is standard of modern medicine. Pharmacogenetics (PGx) has contributed to individualization considering hereditary genetic information; however, increasingly, pharmacogenomics is becoming essential, particularly in relation to modern oncology. New technologies such as next-generation sequencing and rapid development of computational and information sciences will help to better elucidate the consequences of genetic variation, considering also epigenetics and gene-environmental interactions and their translation into clinically relevant individual phenotypes. This review highlights the current challenging and most promising examples of PGx.

引用

页码：S17 / S23

页数：7

共 49 条

[1] Untitled [J].

Abrahams, Edward .

PERSONALIZED MEDICINE, 2009, 6 (05) :479-480

[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[3] CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline [J].

Alfaro, CL ;

Lam, YWF ;

Simpson, J ;

Ereshefsky, L .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) :155-163

[4] A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) [J].

Anderson, Jeffrey L. ;

Horne, Benjamin D. ;

Stevens, Scott M. ;

Woller, Scott C. ;

Samuelson, Kent M. ;

Mansfield, Justin W. ;

Robinson, Michelle ;

Barton, Stephanie ;

Brunisholz, Kim ;

Mower, Chrissa P. ;

Huntinghouse, John A. ;

Rollo, Jeffrey S. ;

Siler, Dustin ;

Bair, Tami L. ;

Knight, Stacey ;

Muhlestein, Joseph B. ;

Carlquist, John F. .

CIRCULATION, 2012, 125 (16) :1997-+

[5] NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation [J].

Barraclough, Katherine A. ;

Isbel, Nicole M. ;

Lee, Katie J. ;

Bergmann, Troels K. ;

Johnson, David W. ;

McWhinney, Brett C. ;

Ungerer, Jacobus P. J. ;

Cambell, Scott B. ;

Leary, Diana R. ;

Bialasiewicz, Seweryn ;

Rockett, Rebecca J. ;

Staatz, Christine E. .

TRANSPLANTATION, 2012, 94 (10) :1025-1032

[6] Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs [J].

Bertilsson, L ;

Dahl, ML ;

Dalén, P ;

Al-Shurbaji, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :111-122

[7] Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients [J].

Binder, Andreas ;

May, Denisa ;

Baron, Ralf ;

Maier, Christoph ;

Toelle, Thomas R. ;

Treede, Rolf-Detlef ;

Berthele, Achim ;

Faltraco, Frank ;

Flor, Herta ;

Gierthmuehlen, Janne ;

Haenisch, Sierk ;

Huge, Volker ;

Magerl, Walter ;

Maihoefner, Christian ;

Richter, Helmut ;

Rolke, Roman ;

Scherens, Andrea ;

Ueceyler, Nurcan ;

Ufer, Mike ;

Wasner, Gunnar ;

Zhu, Jihong ;

Cascorbi, Ingolf .

PLOS ONE, 2011, 6 (03)

[8] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters [J].

Brauch, Hiltrud ;

Schroth, Werner ;

Goetz, Matthew P. ;

Muerdter, Thomas E. ;

Winter, Stefan ;

Ingle, James N. ;

Schwab, Matthias ;

Eichelbaum, Michel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :176-180

[9] The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment [J].

Brockmöller, J ;

Kirchheiner, J ;

Schmider, J ;

Walter, S ;

Sachse, C ;

Müller-Oerlinghausen, B ;

Roots, I .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) :438-452

[10] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].

BROSEN, K ;

OTTON, SV ;

GRAM, LF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549

← 1 2 3 4 5 →